Protagonist Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Protagonist Therapeutics

03/08/2023 22:59

* Protagonist Therapeutics Inc  PTGX.OQ  reported a
quarterly
adjusted loss of 68 cents​​ per share for the quarter ended in
June. The mean expectation of six analysts for the quarter was
for a loss of 65 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Protagonist Therapeutics Inc's reported EPS for the
quarter was
a loss of 68 cents​.
    * The mean earnings estimate of analysts had risen by
about 13.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Protagonist Therapeutics Inc shares had fallen by 32.8%
this
quarter and gained 70.2% so far this year.
    * The company reported a quarterly loss of $38.46 million.
    * Wall Street's median 12-month price target for Protagonist
Therapeutics Inc is $38.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 3 at 09:59 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.65          -0.68          Missed
 Mar. 31 2023      -0.73          -0.67          Beat
 Dec. 31 2022      -0.64          -0.69          Missed
 Sep. 30 2022      -0.87          -0.64          Beat